Treatment method	Stratification*	Grade I recommendations	Grade II recommendations	Grade III recommendations
Neoadjuvant therapy	cT3-4aN + M0, stage cIII		Neoadjuvant therapy: FOLFOX (Evidence 2A) PF (Evidence 2A) XELOX (Evidence 2A) SOX (Evidence 2A) FLOT (Evidence 2A) Postoperative adjuvant therapy after R0 resection to continue the preoperative drug regimen**	Neoadjuvant therapy: ECF (Evidence 2B) mECF (Evidence 2B) After R0 resection, to continue the preoperative drug regimen as postoperative adjuvant therapy**
	cT3-4aN + M0, stage cIII: EGJ carcinoma	Neoadjuvant chemoradiotherapy: DT 45–50.4 Gy (concurrent fluoropyrimidine, platinum or taxanes) (Evidence 1B)	Neoadjuvant chemotherapy (same regimen as above) (Evidence 2A) Neoadjuvant radiotherapy (for patients intolerant of chemotherapy) (Evidence 2B)
	cT4bNanyM0, stage cIVA (no unresectable factors)	MDT discussion for an optimal treatment regimen	Participation in clinical trials is encouraged
	Disease progression after neoadjuvant therapy	MDT discussion for an optimal treatment regimen	Participation in clinical trials is encouraged
	R1/R2 resection after neoadjuvant therapy	MDT discussion for an optimal treatment regimen	Participation in clinical trials is encouraged

FOLFOX leucovorin calcium (folinic acid) + fluorouracil + oxaliplatin, PF cisplatin + 5-fluorouracil (5-FU), FLOT 5-FU + leucovorin + oxaliplatin + docetaxel, ECF epirubicin + cisplatin + 5-FU, mECF modified ECF

* According to the 8th AJCC/UICC clinical staging system (cTNM) for gastric cancer

** For patients who were preoperatively assessed by radiological/pathological examination as having a positive response to neoadjuvant therapy